Fetal/neonatal alloimmune thrombocytopenia

Thromb Res. 2013 Jan:131 Suppl 1:S42-6. doi: 10.1016/S0049-3848(13)70020-3.

Abstract

In fetal/neonatal alloimmune thrombocytopenia (FNAIT), antibodies against paternal antigens present on fetal platelets are produced by the mother. These antibodies will cross the placenta and can cause thrombocytopenia of the unborn. One severe consequence of thrombocytopenia is intracranial bleeding which may lead to death or severe sequelae. FNAIT index cases in one family are usually detected at birth only since antenatal screening programmes have not been installed so far. Subsequent pregnancies of immunized mothers may require special diagnostic and prophylactic interventions, and interdisciplinary counselling and treatment involving obstetricians, pediatricians and immunohematologists may prove useful for optimized care. This short review covers pathogenesis, clinical presentation, diagnostic, and therapeutic options in FNAIT.

Publication types

  • Review

MeSH terms

  • Blood Platelets / metabolism
  • Female
  • Heterozygote
  • Humans
  • Immunoglobulins / therapeutic use
  • Infant, Newborn
  • Infant, Newborn, Diseases / immunology
  • Infant, Newborn, Diseases / therapy
  • Isoantigens / metabolism
  • Male
  • Pregnancy
  • Pregnancy Complications, Hematologic / diagnosis
  • Pregnancy Complications, Hematologic / therapy
  • Prenatal Diagnosis / methods
  • Thrombocytopenia, Neonatal Alloimmune / diagnosis
  • Thrombocytopenia, Neonatal Alloimmune / physiopathology
  • Thrombocytopenia, Neonatal Alloimmune / therapy*

Substances

  • Immunoglobulins
  • Isoantigens